Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Advances in Therapy

• Publication date

  2016-07-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12325-016-0389-3PMID 27438467
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primary open-angle glaucoma

  2016cited by this paper
• One‐year clinical evaluation of 0.4% ripasudil (K‐115) in patients with open‐angle glaucoma and ocular hypertension

  2016cited by this paper
• Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.

  2015cited by this paper
• Intra‐ocular pressure‐lowering effects of a Rho kinase inhibitor, ripasudil (K‐115), over 24 hours in primary open‐angle glaucoma and ocular hypertension: a randomized, open‐label, crossover study

  2015cited by this paper
• Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.

  2013cited by this paper
• Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115.

  2013cited by this paper
• Ocular Hypotensive Dose-response Efficacy and Safety of the Rho Kinase Inhibitor, K-115, in Patients with Primary Open-angle Glaucoma and Ocular Hypertension

  2011cited by this paper
• Effects of K-115, a Rho-Kinase Inhibitor, on Aqueous Humor Dynamics in Rabbits

  2008cited by this paper
• Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys.

  2007cited by this paper
• Primary open-angle glaucoma.

  2004cited by this paper
• The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

  2002cited by this paper
• Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility.

  2001cited by this paper

• Trabecular meshwork: A pivotal target for evolving glaucoma treatments.

  2025cites this paper
• Short-term safety and efficacy of ripasudil as “add-on therapy” in glaucoma patients on maximum tolerable glaucoma medication

  2024cites this paper
• Ocular effects of Rho kinase (ROCK) inhibition: a systematic review

  2024cites this paper
• A comparative study of 0.4% ripasudil, 0.02% netarsudil, and 0.5% timolol in combination with 0.005% latanoprost in the medical management of primary open-angle glaucoma or ocular hypertension

  2024influential citation
• Role of ripasudil as an adjunct treatment in the management of pseudoexfoliative glaucoma

  2023influential citation
• Intraocular pressure-lowering effects of ripasudil on open-angle glaucoma in eyes with high myopia and pathological myopia

  2023influential citation
• Effectiveness of netarsudil 0.02% in lowering intraocular pressure in patients with secondary glaucoma.

  2023cites this paper
• Safety, efficacy, and patient selection of ripasudil in patients with uncontrolled glaucoma with maximum conventional medical therapy

  2022influential citation
• Remodeling of the Lamina Cribrosa: Mechanisms and Potential Therapeutic Approaches for Glaucoma

  2022cites this paper
• Normal‐tension glaucoma: Current concepts and approaches‐A review

  2022influential citation
• The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15

  2021cites this paper
• Design, synthesis, and biological evaluation of urea‐based ROCK2 inhibitors

  2021cites this paper
• Status of Rho kinase inhibitors in glaucoma therapeutics—an overview

  2021cites this paper
• Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma

  2021influential citation
• Responsiveness to ripasudil may be a potential outcome marker for selective laser trabeculoplasty in patients with primary open-angle glaucoma

  2021cites this paper
• Ripasudil Hydrochloride Hydrate in the Treatment of Glaucoma: Safety, Efficacy, and Patient Selection

  2020cites this paper
• One-Year Efficacy and Safety Assessment of Ripasudil, a Rho Kinase Inhibitor, in an Addition to or Replacing Existing Treatment Regimens: A Retrospective Study

  2020influential citation
• Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye.

  2020cites this paper
• OPTH_A_216907 1229..1236

  2020cites this paper
• Long-term Side Effects Including Blepharitis Leading to Discontinuation of Ripasudil

  2019cites this paper
• مهارکنندههای Rho کیناز: درمانی جدید برای گلوکوم و هیپرتانسیون چشمی

  2019cites this paper
• Intraocular pressure-lowering effects of Ripasudil: a potential outcome marker for Trabeculotomy

  2019cites this paper
• What’s New in Medical Management of Glaucoma

  2019cites this paper
• Rho kinase inhibitors—a review on the physiology and clinical use in Ophthalmology

  2019cites this paper
• Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595

  2019cites this paper
• Intraocular Pressure Effects and Mechanism of Action of Topical Versus Sustained-Release Bimatoprost

  2019cites this paper
• Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.

  2018cites this paper
• Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma

  2018cites this paper
• Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma

  2018cites this paper
• Intraocular Pressure-Lowering Effect of Ripasudil Hydrochloride Hydrate and Reasons for Discontinuation of Use in Clinical Practice

  2018cites this paper
• The Anti-Inflammatory Effect of Ripasudil (K-115), a Rho Kinase (ROCK) Inhibitor, on Endotoxin-Induced Uveitis in Rats.

  2017cites this paper
• Targeting Transforming Growth Factor-β Signaling in Primary Open-Angle Glaucoma.

  2017cites this paper
• Targeting Schlemm’s Canal in the Medical Therapy of Glaucoma: Current and Future Considerations

  2017cites this paper
• Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma

  2017cites this paper
• Topical treatment of glaucoma: established and emerging pharmacology

  2017cites this paper
• Efficacy of Ripasudil as a Second-line Medication in Addition to a Prostaglandin Analog in Patients with Exfoliation Glaucoma: A Pilot Study

  2017cites this paper